Finn Guo: Driving a New Era of Accessible Gene Therapy for Hemophilia in China
Finn Guo, Director of Information Research at Illness Challenge Foundation, shared on LinkedIn:
”From launching the project in March to completing the research report ‘Payment Mechanism and Global Strategies for Innovative Hemophilia Therapies’ in June — officially presented at the International Hemophilia Conference.
We started with patient surveys to truly understand the challenges, drew insights from international best practices, and finally developed practical solution frameworks.
While the scheme is still a long way from real-world implementation, I’m truly excited that the rapid progress in China’s domestic gene therapy for hemophilia — combined with current market pricing — is set to usher China into a new era of accessible gene therapy.
Hope is on the horizon.”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 05:36Joining the PACTA Uganda Mental Health and Addiction Community Camp 2026 – Tackle Sickle Cell Africa
-
Nov 17, 2026, 05:30Nathan Connell: Women’s Hematology Summit 2027 to Address Hematologic Health Across the Lifespan
-
Nov 17, 2026, 05:25Mane Kurghinyan: Representing Armenia and HemAI Dynamics at the Falling Walls Lab Global Finale 2026
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter